title: Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
abstract: Infections caused by multidrug-resistantPseudomonas aeruginosa(MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.
authors.affiliation: Clinical Unit of Infectious Diseases, Hospital Universitario Reina Sofía-Instituto Maimónides de Investigación Biomédica (IMIBIC), Córdoba, Spain.|Spanish Network for the Research in Infectious Diseases (REIPI RD12/2015), Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Castón
authors.affiliation: Service of Anesthesiology and Reanimation, Hospital de Jaen, Jaen, Spain.
authors.forename: Álvaro
authors.initials: Á
authors.lastname: De la Torre
authors.affiliation: Department of Infectious Diseases, Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Isabel
authors.initials: I
authors.lastname: Ruiz-Camps
authors.affiliation: Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.
authors.forename: María Luisa
authors.initials: ML
authors.lastname: Sorlí
authors.affiliation: Service of Anesthesia and Reanimation, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
authors.forename: Vicente
authors.initials: V
authors.lastname: Torres
authors.affiliation: Clinical Unit of Infectious Diseases, Hospital Universitario Reina Sofía-Instituto Maimónides de Investigación Biomédica (IMIBIC), Córdoba, Spain julian.torre.sspa@juntadeandalucia.es.|Spanish Network for the Research in Infectious Diseases (REIPI RD12/2015), Instituto de Salud Carlos III, Madrid, Spain.|Universidad de Córdoba, Córdoba, Spain.
authors.forename: Julián
authors.initials: J
authors.lastname: Torre-Cisneros
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality / Q000473:pathology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality / Q000473:pathology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity*; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D012772:Shock, Septic / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D000078142:Tazobactam
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C000594038:ceftolozane, tazobactam drug combination; D010397:Penicillanic Acid; D000078142:Tazobactam
keywords: Pseudomonas aeruginosa; ceftolozane-tazobactam; salvage therapy